Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Biogen Reaffirms 2024 Adjusted EPS Guidance Of $15.00-$16.00, Representing EPS Growth Of Approximately 5% Versus 2023 At The Mid-point Versus Consensus Of $15.48

Author: Benzinga Newsdesk | April 24, 2024 06:53am

Continue to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expect core pharmaceutical revenue (product revenue + LEQEMBI) to be flat vs. 2023
Continue to expect operating income to grow low-double digit percentage vs. 2023 with expected midsingle digit percentage point operating margin improvement

Posted In: BIIB